Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial
John M. Kirkwood(UPMC Hillman Cancer Center), Jeffrey S. Weber(NYU Langone Health), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Christoph Höeller(Medical University of Vienna), Jean‐Jacques Grob(Aix-Marseille Université), Georgina V. Long(The University of Sydney), Jennifer Lord‐Bessen(Bristol-Myers Squibb (United States)), Swetha Srinivasan(Bristol-Myers Squibb (United States)), Fiona Taylor(Adelphi Laboratory Center), Rachael Lawrance(AstraZeneca (Singapore)), Hannah Fairbanks(Adelphi Group (United Kingdom)), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Federico Campigotto(Bristol-Myers Squibb (United States)), Ayman H. Nassar(Cornell University)
Cited by 10
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k